Article Sidebar
Published:
Jan 13, 2015Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Safety of Oral Clemastine – Analysis of Data from Spontaneous Reporting System in Poland
Abstract
Purpose: To analyse the safety of oral clemastine marketed in Poland based on spontaneous adverse event reporting system.
Methods: We analyzed sales volume and data obtained from the monitoring of spontaneous reports on the adverse effects of Clemastinum Hasco tablets (1.0 mg) and Clemastinum Hasco syrup (0.1 mg/mL) received by the manufacturer (PPF HASCO-LEK S.A. Wroclaw, Poland) and National Monitoring Centre in Warsaw in the period January 2007 to June 2012. The Polish system is mainly based on written reports voluntarily submitted by healthcare professionals.
Results: A total of 2,089,717 units of Clemastinum Hasco tablets 1.0 mg and 1,965,340 units of Clemastinum Hasco syrup 0.1 mg/mL were marketed during the period analyzed. Only one spontaneous report on clemastine was registered in the period analyzed.
Conclusion: Oral clemastine is a safe medication, rarely causing adverse effects; Nevertheless, the existing spontaneous monitoring system for adverse effects in Poland may not be sensitive enough and therefore, needs improvement.
Keywords: Clemastine, Adverse drug reactions, Pharmoepidemiology, Drug safety, Pharmacovigilance, Reporting system
